Cargando…

An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury

PURPOSE: This study applies treatment methods to rat retinas subjected to acute ischemia reperfusion injury and compares the efficacy of memantine, hyperbaric oxygen (HBO) therapy, and brimonidine by histopathological examination. METHODS: Thirty adult Wistar albino rats were divided into five group...

Descripción completa

Detalles Bibliográficos
Autores principales: Yiğit, Ulviye, Erdenöz, Serkan, Uslu, Ünal, Oba, Ersin, Cumbul, Alev, Çağatay, Halil, Aktaş, Şamil, Eskicoğlu, Emiray
Formato: Texto
Lenguaje:English
Publicado: Molecular Vision 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084223/
https://www.ncbi.nlm.nih.gov/pubmed/21541269
_version_ 1782202473032712192
author Yiğit, Ulviye
Erdenöz, Serkan
Uslu, Ünal
Oba, Ersin
Cumbul, Alev
Çağatay, Halil
Aktaş, Şamil
Eskicoğlu, Emiray
author_facet Yiğit, Ulviye
Erdenöz, Serkan
Uslu, Ünal
Oba, Ersin
Cumbul, Alev
Çağatay, Halil
Aktaş, Şamil
Eskicoğlu, Emiray
author_sort Yiğit, Ulviye
collection PubMed
description PURPOSE: This study applies treatment methods to rat retinas subjected to acute ischemia reperfusion injury and compares the efficacy of memantine, hyperbaric oxygen (HBO) therapy, and brimonidine by histopathological examination. METHODS: Thirty adult Wistar albino rats were divided into five groups after retinal ischemia was induced by elevating the intraocular pressure to 120 mmHg. The groups were as follows: group 1: control; group 2: acute retinal ischemia (ARI) model but without treatment group; group 3: memantine (MEM) treatment group; group 4: HBO therapy group; and group 5: brimonidine treatment (BRI) group. In the control group, right eyes were cannulated with a 30-gauge needle and removed without causing any intraocular pressure change. The ARI group was an acute retinal ischemia model, but without treatment. In the MEM group, animals were given a unique dose of intravenous 25 mg/kg memantine by the tail vein route after inducing ARI. In the HBO group, at 2 h following ARI, HBO treatment was applied for nine days. In the BRI group, a 0.15% brimonidine tartrate eye drop treatment was applied twice a day (BID) for seven days before ARI. Twenty-one days after establishing ischemia reperfusion, the right eyes were enucleated after the cardiac gluteraldehyde perfusion method, and then submitted to histological evaluation. RESULTS: On average, the total retinal ganglion cell number was 239.93±8.60 in the control group, 125.14±7.18 in the ARI group, 215.89±8.36 in the MEM group, 208.69±2.05 in the HBO group, and 172.27±8.16 in the BRI group. Mean apoptotic indexes in the groups were 1.1±0.35%, 57.71±0.58%, 23.57±1.73%, 15.63±0.58%, and 29.37±2.55%, respectively. CONCLUSIONS: The present study shows that memantine, HBO, and brimonidine therapies were effective in reducing the damage induced by acute ischemia reperfusion in the rat retina. Our study suggests that these treatments had beneficial effects due to neuroprotection, and therefore may be applied in clinical practice.
format Text
id pubmed-3084223
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Molecular Vision
record_format MEDLINE/PubMed
spelling pubmed-30842232011-05-03 An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury Yiğit, Ulviye Erdenöz, Serkan Uslu, Ünal Oba, Ersin Cumbul, Alev Çağatay, Halil Aktaş, Şamil Eskicoğlu, Emiray Mol Vis Research Article PURPOSE: This study applies treatment methods to rat retinas subjected to acute ischemia reperfusion injury and compares the efficacy of memantine, hyperbaric oxygen (HBO) therapy, and brimonidine by histopathological examination. METHODS: Thirty adult Wistar albino rats were divided into five groups after retinal ischemia was induced by elevating the intraocular pressure to 120 mmHg. The groups were as follows: group 1: control; group 2: acute retinal ischemia (ARI) model but without treatment group; group 3: memantine (MEM) treatment group; group 4: HBO therapy group; and group 5: brimonidine treatment (BRI) group. In the control group, right eyes were cannulated with a 30-gauge needle and removed without causing any intraocular pressure change. The ARI group was an acute retinal ischemia model, but without treatment. In the MEM group, animals were given a unique dose of intravenous 25 mg/kg memantine by the tail vein route after inducing ARI. In the HBO group, at 2 h following ARI, HBO treatment was applied for nine days. In the BRI group, a 0.15% brimonidine tartrate eye drop treatment was applied twice a day (BID) for seven days before ARI. Twenty-one days after establishing ischemia reperfusion, the right eyes were enucleated after the cardiac gluteraldehyde perfusion method, and then submitted to histological evaluation. RESULTS: On average, the total retinal ganglion cell number was 239.93±8.60 in the control group, 125.14±7.18 in the ARI group, 215.89±8.36 in the MEM group, 208.69±2.05 in the HBO group, and 172.27±8.16 in the BRI group. Mean apoptotic indexes in the groups were 1.1±0.35%, 57.71±0.58%, 23.57±1.73%, 15.63±0.58%, and 29.37±2.55%, respectively. CONCLUSIONS: The present study shows that memantine, HBO, and brimonidine therapies were effective in reducing the damage induced by acute ischemia reperfusion in the rat retina. Our study suggests that these treatments had beneficial effects due to neuroprotection, and therefore may be applied in clinical practice. Molecular Vision 2011-04-26 /pmc/articles/PMC3084223/ /pubmed/21541269 Text en Copyright © 2011 Molecular Vision. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yiğit, Ulviye
Erdenöz, Serkan
Uslu, Ünal
Oba, Ersin
Cumbul, Alev
Çağatay, Halil
Aktaş, Şamil
Eskicoğlu, Emiray
An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury
title An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury
title_full An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury
title_fullStr An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury
title_full_unstemmed An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury
title_short An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury
title_sort immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084223/
https://www.ncbi.nlm.nih.gov/pubmed/21541269
work_keys_str_mv AT yigitulviye animmunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT erdenozserkan animmunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT usluunal animmunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT obaersin animmunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT cumbulalev animmunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT cagatayhalil animmunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT aktassamil animmunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT eskicogluemiray animmunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT yigitulviye immunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT erdenozserkan immunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT usluunal immunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT obaersin immunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT cumbulalev immunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT cagatayhalil immunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT aktassamil immunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury
AT eskicogluemiray immunohistochemicalanalysisoftheneuroprotectiveeffectsofmemantinehyperbaricoxygentherapyandbrimonidineafteracuteischemiareperfusioninjury